EQS-News
Volta Medical Featured in Latest Consensus Statement from Leading International Cardiac Electrophysiology Societies on Atrial Fibrillation Ablation - Seite 2
The 2024 European Heart Rhythm Association (EHRA)/Heart Rhythm Society (HRS)/Asia Pacific Heart Rhythm Society (APHRS)/Latin American Heart Rhythm Society (LAHRS) expert consensus statement on catheter and surgical ablation of atrial fibrillation represents results from a detailed survey that was sent to all members, a comprehensive literature search and the evaluation of existing evidence. The compiled list of clinical advice was then voted on by the authors, all proposed recommendations were only included if voting results were at least 80% in support. The consensus statement is intended to provide physicians with information to promote optimal care that is aligned with the latest advancements and consensus within the field. The statement has been published in EP Europace Journal (PMCID: PMC11000153)1, the journal of the European Society of Cardiology and the European Heart Rhythm Association.
About Atrial Fibrillation
The American Heart Association (AHA) defines atrial fibrillation (AF) as a quivering or irregular heartbeat (arrhythmia) that can lead to blood clots, stroke, heart failure and other heart-related
complications.2 Approximately 33 million patients worldwide are living with AF.3,4 Even though untreated AF doubles the risk of heart-related deaths and is associated
with a 5-fold increased risk for stroke, many patients are unaware that AF is a serious condition.
Lesen Sie auch
About the TAILORED-AF Trial
TAILORED-AF is an international, multicenter, randomized controlled trial designed to determine if a tailored AI software-guided ablation procedure targeting areas of spatio-temporal dispersion in
combination with pulmonary vein isolation (PVI) is superior to a conventional anatomical ablation targeting PVI alone for the treatment of persistent AF. The primary endpoint of the study is the
absence of documented AF episodes > 30 seconds, with or without anti-arrhythmic drugs (AADs), 12 months after a single index ablation procedure. Secondary endpoints include absence of AF and/or
atrial tachycardia (AT) episodes after a 12- month period, following one or more procedures, as well as safety. Volta Medical expects results from the TAILORED-AF trial in 2024.